- Home
- PSNL vs ETON Comparison
PSNL vs ETON Comparison
Compare PSNL & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | ETON |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PSNL | ETON |
|---|---|---|
| Price | $14.16 | $44.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $12.20 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 4.7M | 524.3K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $69,648,000.00 | ★ $79,950,000.00 |
| Revenue This Year | $15.34 | $40.90 |
| Revenue Next Year | $41.46 | $47.23 |
| P/E Ratio | ★ N/A | $923.60 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $4.43 | $14.27 |
| 52 Week High | $16.39 | $50.18 |
Technical Indicators
Market Signals| Indicator | PSNL | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 63.97 |
| Support Level | $6.68 | $15.77 |
| Resistance Level | $16.39 | $50.18 |
| Average True Range (ATR) | 0.75 | 2.56 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 46.75 | 59.75 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.